Table 5 Univariate analyses of prognostic factors for disease-free survival and overall survival in patients with stage III colon cancer who received curative treatment

Age, year (> 60 vs. ≤ 60))

1.702

(1.057–2.702)

1.465

(0.778–2.758)

Gender (male vs. female)

1.891

(1.132–3.159)

1.877

(0.954–3.693)

BMI, kg/m² (< 18.5 vs. ≥ 18.5)

1.725

(0.538–5.527)

0.775

(0.274–2.191)

Tumor size, cm (> 4 vs. ≤ 4)

0.781

(0.483–1.264)

0.962

(0.516–1.794)

Tumor location

(right-sided colon vs. left-sided colon)

0.798

(0.496–1.285)

0.400

(0.213–1.754)

Differentiation

(poor vs. well/moderately differentiated)

1.354

(0.815–2.248)

1.245

(0.632–2.451)

T stage (T4 vs. T1–3)

1.446

(0.895–2.337)

2.311

(1.170–4.564)

Numbers of resected lymph nodes

(< 12 vs. ≥ 12)

1.356

(0.817–2.250)

0.938

(0.458–1.919)

N stage (N2 vs. N1)

1.334

(0.813–2.190)

1.817

(0.971–3.403)

Preoperative serum CEA, ng/mL

(> 5 vs. ≤ 5)

1.721

(1.072–2.760)

1.104

(0.590–2.067)

Preoperative serum CA19-9, U/mL

(> 24 vs. ≤ 24)

2.674

(1.667–4.288)

2.216

(1.190–4.124)

Risk stratification (high vs. l ow)

1.262

(0.764–2.086)

2.441

(1.122–5.313)

Adjuvant chemotherapy

(unfinished XELOX vs. modified XELOX)

1.668

(1.010–3.057)

3.256

(1.305–8.126)

Adjuvant chemotherapy

(standard XELOX vs. modified XELOX)

0.935

(0.489–1.785)

0.551

(0.207–1.468)